Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation.
Geoerger B, Schiff M, Penard-Lacronique V, Darin N, Saad SM, Duchon C, Lamazière A, Desmons A, Pontoizeau C, Berlanga P, Ducassou S, Yen K, Su M, Schenkein D, Ottolenghi C, De Botton S. Nat Med. 2023 Jun;29(6):1358-1363. doi: 10.1038/s41591-023-02382-9. Epub 2023 May 29. PMID: 37248298.
Therapy-related myelodysplastic syndromes in the genomics era.
Renneville A, Bernard E, Micol JB. Bull Cancer. 2023 Jun 28:S0007-4551(23)00277-1. doi: 10.1016/j.bulcan.2023.02.022. Epub ahead of print. PMID: 37391357.
ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis.
Basso-Valentina F*, Donada A*, Manchev VT, Lisetto M, Balayn N, Martin JE, Muller D, Marin Oyarzun CP, Duparc H, Arkoun A, Cumin A, Faivre L, Droin N, Biunno I, Balduini A, Debili N, Antony-Debré I, Marty C, Vainchenker W, Plo I, Favier R, Raslova H. Haematologica. 2023 Aug 1;108(8):2130-2145.
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A*, Norfo R*, Wen S*, Chédeville A*, Rahman H, O’Sullivan J, Wang G, Louka E, Kretzschmar WW, Paterson A, Brierley C, Martin JE, Demeule C, Bashton M, Sousos N, Moralli D, Subha Meem L, Carrelha J, Wu B, Hamblin A, Guermouche H, Pasquier F, Marzac C, Girodon F, Vainchenker W, Drummond M, Harrison C, Chapman JR, Plo I, Jacobsen SEW, Psaila B, Thongjuea S, Antony-Debré I§, Mead AJ§. Nature Genetics. 2023 Sep 4. doi: 10.1038/s41588-023-01480-1. Epub ahead of print.
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia.
Aid Z, Robert E, Lopez CK, Bourgoin M, Boudia F, Le Mene M, Riviere J, Baille M, Benbarche S, Renou L, Fagnan A, Thirant C, Federici L, Touchard L, Lecluse Y, Jetten A, Geoerger B, Lapillonne H, Solary E, Gaudry M, Meshinchi S, Pflumio F, Auberger P, Lobry C, Petit A, Jacquel A, Mercher T. Leukemia. 2023 Mar;37(3):571-579. doi: 10.1038/s41375-022-01800-0. Epub 2022 Dec 30. PMID: 36585521.
The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions.
Henry E, Picou F, Barroca V, Dechamps N, Sobrino S, Six E, Gobeaux C, Auberger P, Hérault O, Pflumio F, Arcangeli ML.Stem Cells Transl Med. 2023 Aug 24:szad049. doi: 10.1093/stcltm/szad049. Online ahead of print.PMID: 37616262
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.
Marques Da Costa ME, Zaidi S, Scoazec JY, Droit R, Lim WC, Marchais A, Salmon J, Cherkaoui S, Morscher RJ, Laurent A, Malinge S, Mercher T, Tabone-Eglinger S, Goddard I, Pflumio F, Calvo J, Redini F, Entz-Werlé N, Soriano A, Villanueva A, Cairo S, Chastagner P, Moro M, Owens C, Casanova M, Hladun-Alvaro R, Berlanga P, Daudigeos-Dubus E, Dessen P, Zitvogel L, Lacroix L, Pierron G, Delattre O, Schleiermacher G, Surdez D, Geoerger B.Commun Biol. 2023 Sep 18;6(1):949. doi: 10.1038/s42003-023-05320-0.PMID: 37723198
SRSF2-P95H diminue la signalisation JAK/STAT dans les cellules hématopoïétiques et retarde le développement de la myélofibrose chez la souris
Willekens C, Laplane L, Dagher T, Benlabiod C, Papadopoulos N, Lacout C, Rameau P, Catelain C, Alfaro A, Edmond V, Signolle N, Marchand V, Droin N, Hoogenboezem R, Schneider RK, Penson A, Abdel-Wahab O, Giraudier S, Pasquier F, Marty C, Plo I, Villeval JL, Constantinescu SN, Porteu F, Vainchenker W, Solary E. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. Leukemia. 2023 Apr 26. doi: 10.1038/s41375-023-01878-0. Epub ahead of print. PMID: 37100881.